

PREVALENCE AND PREDICTORS OF DIABETES MELLITUS AMONG PERSONS LIVING WITH HIV (PLWH)

3 David Mohammed Umar (Corresponding author)

4 Discipline of Pharmaceutical Sciences, School of Health Sciences, University of KwaZulu-Natal,

5 Westville, Durban, South Africa.

6 Pharmumar2011@gmail.com

7 217075064@stu.ukzn.ac.za

8

9 Prof Panjasaram Naidoo

10 Discipline of Pharmaceutical Sciences, School of Health Sciences, University of KwaZulu-Natal,
11 Westville, Durban, South Africa.

12 naidoopj@ukzn.ac.za

13

14

15

16

17

18

19

20 **Abstract**

21 **Background:** Diabetes mellitus is a chronic non-infectious medical condition which is evident by
22 raised levels of glucose in the blood, because the body cannot produce any or enough of the
23 hormone insulin or use insulin effectively. Diabetes, if not well managed leads to complications
24 such as neuropathy, retinopathy, nephropathy which can be fatal. Some of the factors that
25 predisposes to diabetes include older age, higher body mass index, heredity and hypertension.

26 With the availability of HAART for the managing HIV/AIDS infection, life span of persons living
27 with HIV (PLWH) has increased significantly. With increased longevity, the aging population of
28 PLWH also face chronic diseases such as diabetes in addition to HIV. The burden of both HIV
29 and diabetes is high in South Africa, particularly in KwaZulu-Natal. Nevertheless, the prevalence
30 of diabetes among PLWH in KwaZulu-Natal and its predictors is not well understood. Therefore,
31 this study was conducted to determine the prevalence, predictors of diabetes and the outcome of
32 managing diabetes among PLWH.

33 **Methods:** The study was conducted in four public health care facilities in KwaZulu-Natal after
34 ethical approval and informed consent were obtained. A pretested questionnaire and hospital
35 patient charts were used to collect data. SPSS version was used to analyze the data using
36 descriptive statistics and logistic regression.

37 **Results:** The prevalence of diabetes among PLWH was 9%. This was higher than the prevalence
38 of diabetes of 5.4% among the general population in South Africa. Just over 47% of those who
39 had diabetes, had uncontrolled blood sugar, with a mean fasting blood sugar (FBS) of 11.7
40 mmol/L. The predictors of diabetes among PLWH were, male gender and older age. Male PLWH

41 had 65% less chances of having diabetes and those who were between the ages of 18 and 48 years
42 were 88% less probable to have diabetes compared to those who were older than 48 years.

43 **Conclusion:** Public sector health care facilities in KwaZulu-Natal need to do much more to
44 manage diabetes in PLWH in order to prevent diabetic complications and possible negative impact
45 on the outcome of HIV management.

46 **Key words:** Diabetes, Patient, Factors, HIV, Predictors, Prevalence. PLWH

47

48

49

50

51

52

53

54

55

56

57

58

59

60 **Introduction**

61 “Diabetes is a group of metabolic diseases characterized by hyperglycemia resulting from
62 defects in insulin secretion, insulin action, or both” [1].

63 Insulin is an essential hormone produced in the body's pancreas gland and carries glucose from the
64 bloodstream into the cells of the body where the glucose is transformed into energy. Deficiency of
65 insulin or the cell's failure to respond to insulin results in hyperglycemia, which is a key feature
66 of diabetes.

67 If no intervention is done, hyperglycemia can cause damage to different body organs, resulting to
68 the development of debilitating and life-threatening health problems such as cardiovascular
69 disease, neuropathy, nephropathy and eye disease, resulting in retinopathy and blindness. These
70 complications, however, can be slowed down or avoided if diabetes is appropriately managed.

71 Besides the main types of diabetes, viz Type 1, type 2 and gestational, there is secondary diabetes
72 which arises as a complication of other diseases like pancreatitis, and hormonal disturbances such
73 as Cushing's disease [2].

74 The development of combined antiretroviral therapy has led to the increase in the life span
75 of persons living with HIV (PLWH) with treatment, similar to the expected age of the general
76 population [3,4,5]. With longevity, however, PLWH are developing other chronic medical
77 conditions [6,7,8,9]. One of these chronic comorbidities is diabetes mellitus

78 Factors associated with the development of diabetes in PLWH are the same as those in
79 persons without HIV; they include older age, heredity, higher Body Mass Index [BMI], higher
80 triglyceride, lower total cholesterol and hypertension. However, PLWH have the additional risk
81 factors of HIV and HIV medicines [10,11,12]. Antiretroviral medications, such as nucleoside

82 reverse transcriptase inhibitors (NRTI) and protease inhibitors (PI), have been implicated in
83 causing disorders such as insulin resistance, hyperglycaemia and diabetes [11,13].

84 Irrespective of the factors linked with the development of diabetes in PLWH,
85 understanding the magnitude of the problem and proper management are essential, not only for
86 the prevention of diabetic complications, reduction of mortalities due to the complications or for
87 the improvement in the quality of life but also to prevent possible negative impact on the outcomes
88 of managing HIV. Hence, this study was therefore conducted with the following aim.

89 **Methods**

90 This was a retrospective and a prospective study, aimed at determining the prevalence and
91 predictors of diabetes among persons living with HIV (PLWH) and assessing the outcome of
92 managing diabetes. The study was conducted in 4 HIV clinics at Public Sector Hospitals in the
93 eThekweni Metro of KwaZulu-Natal (KZN), South Africa. These hospitals were selected based on
94 the different former designated racial settlements. A total of 1,203 patients living with HIV that
95 have been on antiretroviral therapy (ART) for at least 6 months, between 2005 and 2019 were
96 randomly selected as follows; letters 'Y' and 'N' were written on separate folded pieces of paper.
97 The patients who consented to participate in the study were asked to pick a folded piece of paper.
98 Those who picked 'Y' were included in the study.

99 The participants had to be 18 years and above, and not pregnant. Those satisfying the criteria were
100 recruited into the study after obtaining their written consent to take part in the study. The following
101 statistical parameters were used to arrive at the minimum sample size of 249 per hospital: Odds
102 ratio = 1.25, type 1 error = 0.05, type 2 error = 0.2 and statistical power = 0.80. Assuming a
103 population variance of 1 and population mean of 0 (normal distribution). A minimum sample size
104 of 996 was determined with a critical Z value = 1.96. Though 996 was required for this study, the

105 number of participants that selected Y was more than the required sample size resulting in a sample
106 size of 1203 which was accepted to allow for dropouts in the study.

107 Data was collected by using both pretested and validated questionnaire and patient chart.

108 The questionnaire was designed to obtain information on patient demographics, other information
109 such as diabetes screening at the clinic, diabetes status, diabetes medication, adherence to
110 hypoglycemic medications by the patients, and life style modification while information on
111 patients management outcomes such as baseline and current CD4 cell counts, baseline and current
112 viral load, initial and current blood sugar were obtained from the hospitals' patient charts and
113 transcribed into a table designed using Microsoft word.

114 The statistical package for social sciences (SPSS) software version 26 was used to analyze the
115 data. Descriptive statistics and logistic regression were used in the analyses of data.

116

117

118

119

120

121

122

123

124

125 **Results**

126 Table 1. Demographic information of patients

Variable	Frequency	Percentage (%)
Gender		
Female	770	64.0
Male	405	33.7
Age in years		
18-28	145	12.6
29-48	694	60.2
>48	313	27.2
Baseline CD4		
<200 cells/ μ L	275	45.5
200-350 cells/ μ L	156	25.8
351-500 cells/ μ L	75	12.4
>500 cells/ μ L	98	16.2

127 Of the 1203 participants, there were more females by close to fifty percent than males, while 28
 128 (2.3%) did not indicate their gender. The age group 29 to 48 years was the majority age group of

129 the participants with just over 60%. Over 45% of the participants still had a CD4 count of less than
130 200.

131

132

133

134

135

136

137

138

139

140

141

142

143

144

145


146

147

148 Figure 1: Prevalence of diabetes among persons living with HIV

149

150



151

152 The prevalence of diabetes among persons living with HIV (PLWH) was 9%, [Fig 1]

153 Over 61% of those having diabetes were diagnosed while already on ART.

154 Over 47% of those with diabetes remained with uncontrolled blood sugar, having a mean FBS of

155 11.7 mmol/L.

156

157

158

159

160

161

162 **Discussion**

163 In this study 9% of the participants living with HIV (PLWH) had diabetes. South Africa, where
164 the study was conducted has a high HIV prevalence as 20.4% of adults between the ages of 15 and
165 49 live with HIV [14]. In addition, the prevalence of diabetes among South Africa's adult general
166 population was 5.4%. [15], yet the prevalence of diabetes among PLWH was much higher at 9%.
167 As shown in this study.

168 This high prevalence of diabetes among PLWH as shown in our study, is consistent with findings
169 by some other earlier studies [16,17,18,12]. However, a study by Diabetes Focus eMag [19]
170 indicated that prevalence of diabetes among PLWH is similar to that among the general population.
171 This difference in findings by different studies may be due to differences in the prevalence of
172 diabetes amongst different populations, or differences in participant's lifestyles.

173 Another finding from this study relating to gender has shown that the prevalence of diabetes among
174 females PLWH was higher (9.5%) than that of males (7.4%). This finding is similar with a study
175 by Hernandez-Ronieu et al, where in 2017 [20], it was shown that the prevalence of diabetes among
176 females living with HIV was higher than that of males living with HIV. However, the same study
177 showed that the prevalence of diabetes is higher in males among the general population.
178 Furthermore, in this South African study it was found that female gender is a predictor for diabetes
179 in PLWH, as males living with HIV were 65% less likely to have diabetes than females. This
180 finding was similar with other studies which indicated that female who are HIV positive are more
181 likely to have non-communicable diseases (NDC) co-morbidity. [21,22]. Hence, females living
182 with HIV should be screened for diabetes repeatedly at close interval, in order to detect diabetes
183 early and manage them accordingly.

184 Though this study found that 61% of the PLWH were diagnosed with diabetes after the
185 commencement of antiretroviral therapy, there was no significant association between when ART
186 was commenced and the incidence of diabetes mellitus. Earlier studies vary in their findings with
187 regards to the association between ART and diabetes, with some studies showing similar results
188 to this study [19], while other studies were contrary to the findings of this study, in that, they
189 showed association between ART and diabetes [23,16,17,18]. While the question whether ART
190 predisposes PLWH to diabetes or not remain controversial, people who test positive for HIV
191 should be tested for diabetes before the commencement of ART and periodically thereafter.

192 Almost half (47.1%) of the PLWH with diabetes in this study remained with uncontrolled blood
193 sugar (Mean FBS of 11.7 mmol/L), this is particularly of concern, as this predisposes them to
194 diabetic complications such as retinopathy, neuropathy, nephropathy among others. These
195 complications, if allowed to occur will further increase the disease burden and pill burden for this
196 group of patients. Therefore, this study further sheds light on this issue to help clinicians
197 understand the burden of diabetes among PLWH and appreciate the possible impact of
198 uncontrolled blood sugar among these patients, with a view to mitigating the impact of the
199 convergence of these chronic conditions by ensuring effective management of diabetes among
200 persons living with HIV.

201 This study also showed that older age is a predictor to diabetes in PLWH, such that the likelihood
202 of diabetes for those older than 48 years of age was 88% compared to those that are younger than
203 48 years of age. This is similar with other studies which showed that old age is a risk factor to
204 chronic comorbidities in PLWH. [21,22]. As ART increases the life span of PLWH, predisposing
205 them to chronic medical conditions such as diabetes, clinicians should give adequate attention to
206 diabetes in PLWH as they do to other comorbidities.

207 However, the current (at the time of the study) blood sugar measurement for some of the patients
208 with diabetes were missing, this might have affected the level of accuracy of the mean fasting
209 blood sugar found in this study (11.7 mmol/L).

210 **Conclusion/recommendations**

211 In KwaZulu-Natal, the prevalence of HIV among PLWH (9%) was higher than that of the general
212 population (5.4%), the prevalence among females was higher (9.5%) than that of males (7.4%)
213 and predictors of diabetes among PLWH were female gender and older age. About half (47.1%)
214 of the people with diabetes had uncontrolled blood sugar with a mean FBS of 11.7 mm/L. There
215 was no association between ART and diabetes. People who test positive to HIV should be tested
216 for diabetes before the commencement of ART, this is to further study the possible association
217 between ART and HIV as some studies indicated. Regular and continuous testing for diabetes
218 should be carried out and those found to be diabetic should be adequately managed to prevent
219 diabetic complications as well as prevent possible interference with the outcomes of managing
220 HIV.

221

222

223

224

225

226

227

228

229

- 230 **List of abbreviations**
- 231 List of abbreviations
- 232 PLWH – Persons Living With HIV
- 233 HIV – Human Immunodeficiency Virus
- 234 AIDS – Acquired Immunodeficiency Syndrome
- 235 FBS - Fasting Blood Sugar
- 236 HAART – Highly Active Antiretroviral Therapy
- 237 BMI – Body Mass Index
- 238 NRTI - Nucleoside Reverse Transcriptase Inhibitors
- 239 PI - Protease Inhibitors
- 240 KZN - KwaZulu-Natal
- 241 ART - Antiretroviral Therapy
- 242 SPSS - Statistical Package for Social Sciences
- 243 BREC - Biomedical Research Ethics Committee
- 244
- 245
- 246
- 247

248 **Declarations**

249 **Ethics approval and consent to participate**

250 Before the commencement of this study, ethical approval was obtained from the biomedical
251 research ethics committee (BREC) of the University of KwaZulu-Natal (UKZN) (Reference
252 number BE 314/18).

253 Each participant read or was read to, the Informed Consent Form from BREC and consented to
254 participate in the study and signed the form before being included in the study.

255 **Consent for publication**

256 Not applicable

257 **Availability of data and materials**

258 The datasets used and/or analyzed during the current study are available from the corresponding
259 author on reasonable request.

260 **Competing interests**

261 The authors declare that they have no competing interests

262 **Funding**

263 The College of Health Sciences Research office provided stipends to the corresponding author,
264 funded logistics such as transportation to collect data and funded the cost of printing the research
265 instruments (questionnaire and information sheet). But it was not involved in any way in the design

266 of the study, was not involved in the data collection. Was not involved in any way in the analysis,
267 interpretation of data or in writing the manuscript.

268 **Authors' contribution**

269 **DMU** conceptualized the study, designed the work, collected data alongside 2 research assistants,
270 analyzed and interpreted the data with the guidance of a statistician.

271 **DMU** has approved the submitted version of this manuscript and has agreed both to be accountable
272 for his contributions and to ensure that questions related to the accuracy or integrity of any part of
273 the work even ones in which he was not personally involved, are appropriately investigated,
274 resolved, and the resolution documented in the literature

275 **PN** revised, the proposal, the questionnaire, the information sheet, draft manuscript and the final
276 manuscript.

277 **PN** has approved the submitted version of this manuscript and has agreed both to be accountable
278 for her contributions and to ensure that questions related to the accuracy or integrity of any part of
279 the work even ones in which she was not personally involved, are appropriately investigated,
280 resolved, and the resolution documented in the literature

281 **Acknowledgements**

- 282 ➤ Professor Sihawukile Ngubane for kindly translating the questionnaire and informed
283 consent form from English language to isiZulu.
- 284 ➤ Miss Ncomeka Sineke for her assistance in data collection.
- 285 ➤ Mr Zerisenay Beyene Tsegay for his assistance in data collection
- 286 ➤ Mr Zelalem Dessie (statistician) who guided with statistical analysis and interpretation.

287 **References**

- 288 1. American Diabetes Association. (2014) Diagnosis and classification of diabetes mellitus.
289 *Diabetes Care.* 2014; 37 Suppl 1 S81-S90
- 290 2. International Diabetes Federation (IDF) Diabetes Atlas, 8th edition 2017.
291 www.diabetesatlas.org
- 292 3. Althoff KN, McGinnis KA, Wyatt CM, Freiberg MS, Gilbert C, Oursler KK, et al. For the
293 Veterans Aging Cohort Study (VACS). Comparison of Risk and Age at Diagnosis of
294 Myocardial Infarction, End-Stage Renal Disease, and non-AIDS-Defining Cancer in HIV-
295 Infected Versus Uninfected Adults. *HIV/AIDS. CID* 2015; 60
- 296 4. Nakagawa F, Lodwick RK, Smith CJ, Smith R, Cambiano V, Lundgren JD, et al. Projected
297 life expectancy of people with HIV according to timing of diagnosis. *AIDS* 2012; 26:335-
298 343
- 299 5 Samji H, Cescon A, Hogg RS, Modur SP, Althoff KN, Buchacz K, et al. For the North
300 American AIDS cohort collaboration on Research and Design (NA-ACCORD) of ieDEA.
301 Closing the Gap: Increases in Life Expectancy among Treated HIV Positive Individuals in
302 the United States and Canada. *PLOS ONE.* 2013; 8(12), e81355. www.plosone.org
- 303 6 Cailhol J, Nkurunziza B, Izzidine H, Nindagiye E, Munyana L, Baramperanye E, et al.
304 Prevalence of chronic kidney disease among people living with HIV/AIDS in Burundi: a
305 cross-sectional study. *BMC Nephrology.* 2011; 12:40
- 306 7 Calza L, Vanino E, Magistrelli E, Salvadori C, Cascavilla A, Colangeli V, et al. Prevalence
307 of renal disease within an urban HIV-infected cohort in northern Italy. *Clin Exp Nephrol.*
308 2014; 18:104-112

- 309 8 Campbell LJ, Ibrahim F, Fisher M, Holt SG, Hendry BM and Post FA. Spectrum of chronic
310 kidney disease in HIV-infected patients. *HIV medicine*. 2009; 10:329-336
- 311 9 Winston JA. HIV and CKD Epidemiology. *Adv Chronic Kidney Dis.* 2010; 17(1):19-25.
- 312 10 Galli L, Salpietro S, Pellicciotta G, Galliani A, Piatti P, Hasson H, et al. Risk of type 2
313 diabetes among HIV-infected and healthy subjects in Italy. *Eur J Epidemiol.* 2012; 27 (8):
314 657-665.
- 315 11 Rasmussen LD, Mathiesen ER, Kronborg G, Pedersen C, Gerstoft J and Obel N. Risk of
316 diabetes mellitus in persons with and without HIV: a Danish nationwide population-based
317 cohort study. *PLoS ONE.* 2012; 7: e44575 doi: 10.1371/journal.pone.0044575
- 318 12 Abebe SM, Getachew A, Fasika S, Bayisa M, Demisse AG and Mespin N. Diabetes mellitus
319 among HIV-infected individuals in follow-up care at University of Gondar Hospital,
320 Northwest Ethiopia. *BMJ Open.* 2016; 6: e011175. Doi:10.1136/bmjopen-2016-011175.
- 321 13 Dimala CA, Atashili J, Mbuagbaw JC, Wilfred A and Monekosso GL. A Comparison of the
322 Diabetes Risk Score in HIV/AIDS patients on Highly Active Antiretroviral Therapy
323 (HAART) and HAART-Naïve Patients at the Limbe Regional Hospital, Cameroon. *PLOS*
324 *ONE.* 2016.
- 325 14 UNAIDS HIV and AIDS in South Africa. 2019 <https://www.avert.org/professionals/hiv-around-world/sub-saharan-africa/south-africa> Accessed 13th January, 2020.
- 326 15 International diabetes federation (IDF) <https://www.idf.org/our-network/regions-members/africa/members/25-south-africa.html> accessed 1st February, 2020.06.04.
- 327 16 Samara K. The burden of diabetes and hyperlipidemia in treated HIV infection and
328 approaches for cardiometabolic care. *Curr HIV/AIDS Rep.* 2012; 9(3): 469-78.12

- 331 17 Hadigan C and Kattakuzhy S. Diabetes mellitus type 2 and abdominal glucose metabolism
332 in the setting of human immunodeficiency virus. Endocrinol Metab Clin North Am. 2014;
333 43(3): 685-96.
- 334 18 Paik IJ and Kotler DP. The prevalence and pathogenesis of diabetes mellitus in treated HIV
335 infection, Best Pract Res Clin Endocrinol Metab. 2011; 25 (3): 469-78.
- 336 19 Diabetes Focus eMag. Type 2 diabetes and HIV, Diabetes South Africa. Posted 24 Oct 2017
337 Available at: <https://www.diabetessa.org.za/type-2-diabetes-hiv/> Accessed on 8 May,
338 2019].
- 339 20 Hernandez-Romieu AC, Garg S, Rosenberg ES, Thompson-Paul AM and Skarbinski J. Is
340 diabetes prevalence higher among HIV-infected individuals compared with the general
341 population? Evidence from MMP and NHANES 2009-2010. BMJ Open Diabetes Research
342 and Care. 2017; 5: e000304. doi: 10.1136/bmjdrc-2016-000304
- 343 21 Castilho JL, Escuder MM, Veloso V, Gomes JO, Jayathilake1 K, Ribeiro S, et al. Trends
344 and predictors of non-communicable disease multimorbidity among adults living with HIV
345 and receiving antiretroviral therapy in Brazil. Journal of the International AIDS Society.
346 2019; 22:e25233
347 <http://onlinelibrary.wiley.com/doi/10.1002/jia2.25233/fullhttps://doi.org/10.1002/jia2.252>
348 33
- 349 22 Palella FJ, Hartb R, Armonb C, Tedaldic E, Yangcod B, Novake R, et al. For the HIV
350 Outpatient Study (HOPS), Non-AIDS comorbidity burden differs by sex, race, and
351 insurance type in aging adults in HIV care. AIDS. 2019; 33:2327–2335
- 352 23 Paengsai N, Jourdain G, Chaiwarith R, Tantraworasin A, Bowonwatanuwong C,
353 Bhakeecheep S, et al. Incidence and clinical outcomes of diabetes mellitus in HIV-infected

354 adults in Thailand: a retrospective cohort study. BMC Public Health. 2018; 18(1079)
355 <https://doi.org/10.1186/s12889-018-5967-7>

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376 Table 2. Association between patient variables and diabetes among PLWH taking ART.

377 (Table 2 should appear below table 1 in the text file)

378

Variables	Diabetes, n (%)		Total frequency, n (%)	Chi-square P-value
	No	Yes		
Gender				
Male	363(92.4)	30(7.6)	393(34.6)	0.219
Female	669(90.2)	73(9.8)	742(65.4)	
Age				
18 – 28	139 (99.3)	1(0.7)	140(12.5)	0.000*
29-48	643(95.3)	32(4.7)	675(60.5)	
>48	233(77.4)	68(22.6)	301(27.0)	
Level of Education				
No formal education	40(87.0)	6(13.6)	46(4.2)	0.109
Primary	175(87.1)	26(12.9)	201(18.5)	
High school	601(92.2)	51(7.8)	652(60.0)	
Tertiary	173(92.0)	15(8.0)	188(17.3)	
Employment Status				
Employed	349(93.6)	24(6.4)	373(32.6)	0.030*

unemployed	692(89.6)	80(10.4)	772(67.4)	
Alcohol consumption				
Yes	189(92.2)	16(7.8%)	205(18.1)	0.505
No	841(90.7)	86(9.3)	927(81.9)	
Initial CD4 count (cells/mm3)				
<200	234(88.6)	30(11.4)	264(44.9)	0.414
200 - 350	142(91.0)	14(9.0)	156(26.5)	
351 - 500	68(93.2)	5(6.8)	73(12.4)	
>500	89(93.7)	6(6.3)	95(16.2)	
Current CD4 count (cells/mm3)				
<200	50(94.3)	3(5.7)	53(8.3)	0.386
200 - 350	99(93.4)	7(6.6)	106(16.7)	
351 - 500	133(90.5)	14(9.5)	147(23.1)	
>500	293(88.8)	37(11.2)	330(51.9)	
Initial viral load (copies/mm3)				

High (≥100,000)	22(95.7)	1(4.3)	23(14.6)	0.137
Low (10,000 – 99,000)	19(79.2)	5(20.8)	24(15.3)	
Lower (<10,000)	100(90.9)	10(9.1)	110(70.1)	
Current viral load (cells/mm3)				
‘Detectable’	340(90.9)	34(9.1)	374(59.0)	0.587
LTDL	233(89.6)	27(10.4)	260(41.0)	

379 Key: * = Statistically significant

380 As can be seen from table 2 above, there was statistically significant association between the age
381 and employment status of PLWH and having diabetes, at 95% confidence level.

382

383

384

385

386

387

388

389 Table 3: Predictors of diabetes in PLWH on ART (Multi-covariate and uni-covariate logistic
390 regression).

391 (Table 3 should appear below table 2 in the text file)

392

Variables	COR (95%CI)	COR P-Value	aOR(95%CI)	aOR P-Value
Gender				
Male	0.76(0.49-1.18)	0.220	0.35(0.15-0.82)	0.016*
Female	1		1	
Age				
18 – 48	0.14(0.09-0.22)	0.000*	0.12(0.06-0.26)	0.000*
>48	1		1	
Duration on ART				
			1(0.99-1.01)	0.473
Level of education				
No formal education	1.73(0.63-4.74)	0.286		
Primary	1.71(0.88-3.35)	0.115		
High school	0.98(0.54-1.78)	0.944		
Tertiary	1			

Employment Status				
Employed	0.60(0.37-0.96)	0.032*		
unemployed	1			
Alcohol consumption				
Yes	0.83(0.48-1.44)	0.506		
No	1			
Baseline CD4 cells count				
>200 cells/ μ L			1.90(0.91-3.98)	0.088
\leq 200 cells/ μ L			1	
Current CD4 cells count				
>200 cells/ μ L			1.04(0.25-4.32)	0.957
\leq 200 cells/ μ L			1	

393 Keys: 1 = the reference category; COR= Crude Odd Ratio; CI= Confidence interval; aOR =

394 Adjusted Odd Ratio (Logistic regression).

395

396 In a stepwise forward likelihood ratio multivariate logistic regression model (as shown in table 3
397 above), female gender and age were predictors of diabetes in PLWH on ART.

398 The probability for diabetes mellitus in male PLWH on ART was 65% less than that of females
399 (aOR = 0.35, 95% CI= 0.15-0.82, P-value=0.016).

400 The likelihood of diabetes mellitus in PLWH on ART who were between the ages 18 and 48 years
401 was 88% less than those that were older than 48 years. (aOR = 0.12, 95% CI= 0.06-0.26, P-
402 value=0.000)

403

404

405

406